Candriam SCA’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$129M Sell
510,174
-288,641
-36% -$67.3M 0.58% 33
2026
Q1
$195M Buy
798,815
+49,216
+7% +$11.5M 1.01% 13
2025
Q4
$155M Buy
749,599
+113,575
+18% +$22.5M 0.77% 23
2025
Q3
$118M Buy
636,024
+340,354
+115% +$58.3M 0.62% 31
2025
Q2
$45.2M Sell
295,670
-3,444
-1% -$529K 0.26% 89
2025
Q1
$49.6M Buy
299,114
+22,060
+8% +$3.45M 0.31% 83
2024
Q4
$40.1M Buy
277,054
+11,902
+4% +$1.84M 0.23% 88
2024
Q3
$43M Sell
265,152
-15,083
-5% -$2.4M 0.25% 84
2024
Q2
$41M Buy
280,235
+6,736
+2% +$1M 0.25% 89
2024
Q1
$43.3M Sell
273,499
-33,731
-11% -$5.37M 0.28% 81
2023
Q4
$48.2M Sell
307,230
-179,678
-37% -$27.6M 0.33% 73
2023
Q3
$75.8M Sell
486,908
-332,735
-41% -$54.9M 0.54% 34
2023
Q2
$136M Sell
819,643
-43,858
-5% -$7.08M 0.98% 16
2023
Q1
$123M Buy
863,501
+172,445
+25% +$27.8M 0.85% 18
2022
Q4
$122M Buy
691,056
+195,274
+39% +$33.7M 0.82% 18
2022
Q3
$81M Sell
495,782
-145,989
-23% -$24.7M 0.57% 30
2022
Q2
$114M Sell
641,771
-229,897
-26% -$41M 0.94% 16
2022
Q1
$154M Sell
871,668
-3,638
-0.4% -$619K 1.05% 16
2021
Q4
$150M Sell
875,306
-107,120
-11% -$17.5M 0.96% 15
2021
Q3
$159M Buy
982,426
+337,232
+52% +$57.5M 1.08% 11
2021
Q2
$106M Buy
645,194
+41,249
+7% +$6.83M 0.73% 24
2021
Q1
$91.3M Sell
603,945
-7
-0% -$1.13K 0.76% 23
2020
Q4
$95M Buy
603,952
+187,791
+45% +$27.7M 0.75% 23
2020
Q3
$62M Buy
416,161
+5,780
+1% +$855K 0.58% 34
2020
Q2
$57.7M Buy
410,381
+14,735
+4% +$2.15M 0.61% 31
2020
Q1
$56.4M Buy
395,646
+40
+0% +$5.67K 0.63% 28
2019
Q4
$57.7M Sell
395,606
-20,887
-5% -$2.83M 0.62% 28
2019
Q3
$53.9M Buy
416,493
+3,961
+1% +$522K 0.71% 24
2019
Q2
$62.2M Buy
412,532
+13,912
+3% +$1.93M 0.78% 21
2019
Q1
$61M Buy
398,620
+21,096
+6% +$2.83M 0.78% 23
2018
Q4
$48.7M Sell
377,524
-47,205
-11% -$6.58M 0.75% 24
2018
Q3
$58.7M Buy
424,729
+236
+0.1% +$31.4K 0.78% 22
2018
Q2
$51.5M Buy
424,493
+5,223
+1% +$652K 0.82% 19
2018
Q1
$53.7M Buy
419,270
+84,393
+25% +$11.4M 0.92% 14
2017
Q4
$46.8M Sell
334,877
-199,812
-37% -$27.8M 0.81% 15
2017
Q3
$69.5M Buy
534,689
+26,071
+5% +$3.46M 1.21% 10
2017
Q2
$67.3M Sell
508,618
-10,186
-2% -$1.3M 1.26% 9
2017
Q1
$64.6M Sell
518,804
-444,987
-46% -$53.2M 1.25% 11
2016
Q4
$111M Buy
963,791
+210,925
+28% +$24.4M 2.55% 2
2016
Q3
$88.9M Buy
752,866
+23,922
+3% +$2.9M 2.14% 3
2016
Q2
$88.4M Buy
728,944
+179,216
+33% +$20.4M 2.3% 2
2016
Q1
$59.2M Sell
549,728
-271,111
-33% -$28.1M 1.48% 8
2015
Q4
$84.3M Sell
820,839
-207,632
-20% -$20.9M 2.26% 4
2015
Q3
$96M Buy
1,028,471
+47,086
+5% +$4.55M 2.36% 3
2015
Q2
$95.6M Buy
981,385
+18,573
+2% +$1.86M 1.99% 4
2015
Q1
$96.9M Buy
962,812
+420,546
+78% +$42.8M 1.95% 2
2014
Q4
$56.7M Buy
+542,266
New +$57.1M 1.19% 8

Other funds holding JNJ

Candriam SCA's JNJ Position: Q2 2026 in Review

Candriam SCA reduced its Johnson & Johnson (JNJ) stake by 36% in Q2 2026, selling an estimated $67.3M and leaving 510,174 shares worth $129M. The position accounts for 0.58% of the portfolio, ranked #33.

Candriam SCA first reported a position in JNJ in Q4 2014 and has held it in 47 quarters since. The position peaked at $195M in Q1 2026. 4,655 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Candriam SCA held 510,174 shares of Johnson & Johnson worth $129M as of Q2 2026.
  • Candriam SCA sold 288,641 Johnson & Johnson shares in Q2 2026, an estimated $67.3M.
  • Johnson & Johnson made up 0.58% of Candriam SCA's portfolio in Q2 2026, its #33 holding.
  • Candriam SCA first reported a position in Johnson & Johnson in Q4 2014 and has held it in 47 quarters since.
  • Candriam SCA's Johnson & Johnson position peaked at $195M in Q1 2026.
  • 4,655 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.